Skip to Content

Humoral Response to COVID-19 Vaccines in patients with CLL

Immunosuppressed individuals such as chronic lymphocytic leukemia (CLL) patients are at risk for a suboptimal response to 2 vaccine doses, According to the use of a third dose in immunosuppressed patient – the seroconversion rate after the triple-dose vaccine is not yet known. This study evaluates SARS-CoV-2 antibody responses after the first, second and third doses of the Pfizer–BioNTech COVID-19 vaccine and the vaccine from Moderna. You will also get the answer of how many who remained seronegative after the second dose and the answer of the strongest boost to immune response against the virus.

Florence Ajchenbaum-Cymbalista

Lue artikkeli

Jos olet lääkäri, farmaseutti tai rajatun lääkkeenmääräämisoikeuden omaava sairaanhoitaja, pääset lukemaan artikkelin kirjautumalla käyttäjäksi BestPractice Nordic -sivustolle.

Back to top